Headlines about Masimo Corporation (NASDAQ:MASI) have trended somewhat positive on Sunday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Masimo Corporation earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.0686603570379 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
Masimo Corporation (NASDAQ MASI) opened at 85.01 on Friday. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of 13.93 and a beta of 0.82. Masimo Corporation has a one year low of $53.78 and a one year high of $104.71. The firm has a 50-day moving average price of $85.41 and a 200-day moving average price of $89.89.
Masimo Corporation (NASDAQ:MASI) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.12. The company had revenue of $192.90 million during the quarter, compared to analyst estimates of $189.03 million. Masimo Corporation had a return on equity of 23.45% and a net margin of 45.90%. The firm’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.57 earnings per share. On average, equities analysts predict that Masimo Corporation will post $2.80 earnings per share for the current year.
A number of research analysts have recently issued reports on the company. Roth Capital increased their target price on Masimo Corporation from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, July 19th. BidaskClub lowered Masimo Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Zacks Investment Research upgraded Masimo Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Stifel Nicolaus initiated coverage on Masimo Corporation in a report on Monday, July 10th. They issued a “buy” rating and a $105.00 price objective on the stock. Finally, BTIG Research upgraded Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. Masimo Corporation has an average rating of “Hold” and an average target price of $97.00.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/15/masimo-corporation-masi-receiving-somewhat-favorable-press-coverage-analysis-finds.html.
In other Masimo Corporation news, insider Jon Coleman sold 25,000 shares of the company’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $97.50, for a total transaction of $2,437,500.00. Following the completion of the sale, the insider now directly owns 32,201 shares in the company, valued at $3,139,597.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sanford Fitch sold 11,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $87.25, for a total value of $959,750.00. Following the sale, the director now owns 72,249 shares of the company’s stock, valued at $6,303,725.25. The disclosure for this sale can be found here. Corporate insiders own 16.60% of the company’s stock.
About Masimo Corporation
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with MarketBeat.com's FREE daily email newsletter.